Prosecution Insights
Prosecution Insights
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| Double-patenting only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JACKSON, SHAWQUIA | 1 | 77.9% | -3.3% |
| YU, MISOOK | 1 | 38.9% | +17.7% |
| PALENIK, JEFFREY T | 1 | 53.8% | +26.8% |
| MIKNIS, ZACHARY J | 1 | 68.3% | +32.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18330748 | PEPTIDES FOR INCREASING DRUG DELIVERY TO CANCER | MIKNIS, ZACHARY J | 75d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18452405 | EGFR TARGETING PEPTIDE CONJUGATE | YU, MISOOK | 58d overdue |
| 18330748 | PEPTIDES FOR INCREASING DRUG DELIVERY TO CANCER | MIKNIS, ZACHARY J | 75d |
| 18222775 | NANOMEDICINES FOR TREATMENT OF DISEASE | PALENIK, JEFFREY T | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1615 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18821660 | USE OF NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS FOR IMMUNOTHERAPY IN MELANOMA PATIENTS | JACKSON, SHAWQUIA | — | DP | Non-Final OA | — | Pending | Aug 30, 2024 |
| 18452405 | EGFR TARGETING PEPTIDE CONJUGATE | YU, MISOOK | 1641 | §103 | Final Rejection | 58d overdue | Pending | Aug 18, 2023 |
| 18222775 | NANOMEDICINES FOR TREATMENT OF DISEASE | PALENIK, JEFFREY T | 1615 | §103 | Non-Final OA | — | Pending | Jul 17, 2023 |
| 18330748 | PEPTIDES FOR INCREASING DRUG DELIVERY TO CANCER | MIKNIS, ZACHARY J | 1658 | §102§103§112 | Non-Final OA | 75d | Pending | Jun 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial